Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post‐hematopoietic stem cell transplant for dyskeratosis congenita due to <i> <scp>TINF</scp> 2 </i> mutation

Niall O'Connell, Matthew Goodyer, Mary Gleeson, Lorna Storey, Martina Williams, Melanie Cotter, Aengus O’Marcaigh, Owen Smith

Pediatric Transplantation · 2013 · 18 citations · 8 references

Concepts

Abstract

AIHA following allogeneic HSCT is appearing more frequently in the literature. It occurs as a result of donor cell-derived antibodies targeting donor red cell antigens. Little guidance exists on the management of such patients, particularly in the pediatric setting. First-line conventional treatment is corticosteroids and/or immunoglobulin therapy with monoclonal antibody therapy reserved for treatment failure. We report our experience of a child refractory to immunoglobulin and steroid therapy who required several infusions of rituximab and immunomodulatory therapy to obtain a clinically significant response.

References

8